2nd ADC Toxicity Summit

Kongressthemen
Toxicities continue to pose the most significant challenge in the progression of antibody-drug conjugates to the clinic, and with increasing companies entering into the ADC space and tackling toxicity, there is ever-increasing target and indication-competition. Considering the significant clinical setbacks witnessed in 2023, the demand to better understand the translatability of toxicities and develop more tolerable ADCs for achieving future clinical triumphs only grows stronger.

Wissenschaftliche Fach-Gesellschaft
Hanson Wade Group

Anmerkungen
Brochure: https://go.evvnt.com/2381308-3?pid=4832

Speakers: Ali Warbington, Director, Toxicology, ImmunoGen, Arnima Bisht, Senior Director, Oxford BioTherapeutics and More.

https://go.evvnt.com/2381308-2?pid=4832

Herr Luke Kelly